Switching kidney cancer treatment after first therapy stops working
Part of Cancer, Kidney & urinary clinical trials.
This study tests what happens when people with advanced kidney cancer switch their treatment after the first one stops working. It looks at two different switch options: going from a TKI to a TKI plus immunotherapy, or from a TKI plus immunotherapy back to a TKI.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have metastatic kidney cancer that cannot be removed with surgery.
- Your previous treatment (either a TKI or TKI plus immunotherapy) stopped working or caused bad side effects.
- You are age 18 or older and of Chinese descent.
- Your kidney cancer is classified as low or intermediate risk by your doctor.
- You are in generally good health (able to care for yourself) and have adequate organ function.
- You do not have other serious conditions like uncontrolled heart disease, active infections, or other cancers that need treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of three drugs—atorvastatin, axitinib, and toripalimab—to treat advanced clear-cell renal cell carcinoma (a common type of kidney cancer that has spread or cannot be surgically removed). The drugs work by targeting blood vessel growth and boosting the immune system to fight cancer cells.
This trial tests if a combination of targeted embolization, immunotherapy (Toripalimab), and a targeted therapy pill (Axitinib) can shrink advanced kidney cancer before surgery. It is for patients whose cancer has spread to nearby tissues or lymph nodes, or has limited spread elsewhere that can be removed.
This trial tests a combination of targeted therapy (axitinib) and immunotherapy (toripalimab) alongside stereotactic body radiation therapy (SBRT) for kidney cancer that has come back or spread. It may be an option if you have a limited number of metastatic tumors that can be treated with radiation.
This trial tests if people with advanced kidney cancer can safely stop all treatment if a special scan (PET/CT) shows their cancer has shrunk or disappeared. It's for those who have already been on a first-line immunotherapy plus targeted therapy for at least 12 months.
This trial tests whether starting immunotherapy (a type of medicine that helps your immune system fight cancer) right away, and delaying surgery to remove the kidney tumor, is a safe and effective approach for people with advanced kidney cancer that has spread. It may help you avoid or delay surgery while still controlling the cancer.
This trial tests whether removing or burning (ablating) the main kidney tumor helps people with advanced kidney cancer who are already doing well on immunotherapy. Researchers want to see if combining local treatment with ongoing immunotherapy can improve outcomes.
Hear when a new RCC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.